Tenaya Therapeutics, Inc. (TNYA): Price and Financial Metrics
GET POWR RATINGS... FREE!
TNYA Stock Price Chart Interactive Chart >
TNYA Price/Volume Stats
|Current price||$3.12||52-week high||$32.00|
|Prev. close||$3.01||52-week low||$2.77|
|Day high||$3.23||Avg. volume||158,496|
|50-day MA||$4.38||Dividend yield||N/A|
|200-day MA||$8.78||Market Cap||129.06M|
Tenaya Therapeutics, Inc. (TNYA) Company Bio
Tenaya Therapeutics, Inc. develops therapeutics for heart failure. It offers cellular regeneration platform, that enables in vivo reprogramming of cardiac fibroblasts into cardio myocytes by delivering proprietary transcription factors; gene therapy platform, that enables the targeted delivery of a payload to cardiac fibroblasts; and precision medicine platform, which provides personalized medicine approach to treat heart disease. The company was incorporated in 2016 and is based in South San Francisco, California.
Most Popular Stories View All
TNYA Latest News Stream
|Loading, please wait...|
TNYA Latest Social Stream
View Full TNYA Social Stream
Latest TNYA News From Around the Web
Below are the latest news stories about TENAYA THERAPEUTICS INC that investors may wish to consider to help them evaluate TNYA as an investment opportunity.
Tenaya Therapeutics to Participate in Inaugural Hypertrophic Cardiomyopathy Medical Society’s 2022 Scientific Sessions
Encore Presentation of Lead Gene Therapy TN-201 Preclinical Data to be Featured in Late-Breaking Trials SessionSOUTH SAN FRANCISCO, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, announced today that it is scheduled to participate in the Hypertrophic Cardiomyopathy Medical Society’s (HCMS)
SOUTH SAN FRANCISCO, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, announced today that Faraz Ali, Chief Executive Officer, is scheduled to participate in the Chardan 6th Annual Genetic Medicines Conference and the Alliance for Regenerative Medicine’s Cell and Gene Meeting on the Mesa. Det
In this article, we will look at the 10 best biotech stocks under $10. If you want to explore similar biotech stocks with promising prospects that you can get for under $10, you can also take a look at 5 Best Biotech Stocks Under $10. The Global Biotech Industry According to an industry analysis report […]
In this article, we will look at Harvard University’s latest stock portfolio and list its 10 best biotech stock picks. If you want to explore more biotech stocks that make up the top holdings of Harvard Management, you can also take a look at Harvard University’s Latest Portfolio: 5 Best Biotech Stock Picks. Harvard Management […]
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Tenaya Therapeutics (TNYA - Research Report) today and set a price target of $25.00. The company's shares opened today at $4.75.According to TipRanks, Pantginis is an analyst with an average return of -21.1% and a 27.68% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Humanigen, Astria Therapeutics, and Celldex.Tenaya Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $29.75.See today’s best-performing stocks on TipRanks >>The company has a one-year high of $32.00 and a one-year low of $4.15. Currently, Tenaya Therapeutics has an average volume of 172.9K.
TNYA Price Returns